Abbott Laboratories
ABT
$123.62
-$1.05-0.84%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 142.36% | 151.56% | 139.82% | 134.18% | 11.72% |
| Total Depreciation and Amortization | -2.88% | -3.26% | -2.25% | -0.77% | -0.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.64% | 42.27% | 43.76% | 50.00% | -6.74% |
| Change in Net Operating Assets | -757.56% | -440.68% | -251.35% | -272.40% | 60.70% |
| Cash from Operations | 4.48% | 14.39% | 25.30% | 17.86% | 33.27% |
| Capital Expenditure | 1.78% | -0.71% | -3.29% | -0.23% | -8.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 41.18% | -- | -- | 100.00% |
| Divestitures | -100.00% | -100.00% | -97.50% | -97.50% | -97.50% |
| Other Investing Activities | -60.00% | -450.00% | -133.33% | -40.43% | -17.02% |
| Cash from Investing | -3.44% | -7.53% | 23.03% | 25.38% | 21.93% |
| Total Debt Issued | -98.36% | -97.94% | 873.91% | 869.57% | 2,118.18% |
| Total Debt Repaid | -95.21% | 38.76% | 35.35% | 69.58% | 27.98% |
| Issuance of Common Stock | 52.38% | 85.23% | 74.48% | 58.08% | 56.90% |
| Repurchase of Common Stock | 26.88% | -175.92% | -47.75% | -5.54% | 25.05% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.38% | -7.55% | -7.78% | -7.87% | -7.88% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -21.05% | -3.62% | 8.37% | 23.79% | 13.87% |
| Foreign Exchange rate Adjustments | -250.00% | 152.83% | 46.27% | -317.39% | 300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -105.54% | 95.75% | 108.62% | 124.11% | 129.43% |